KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $24.0 million.

  • Rigel Pharmaceuticals' Cash from Operations rose 1084.92% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.2 million, marking a year-over-year increase of 53551.45%. This contributed to the annual value of $31.5 million for FY2024, which is 64798.89% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Cash from Operations stood at $24.0 million for Q3 2025, which was up 1084.92% from $30.5 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Cash from Operations ranged from a high of $55.2 million in Q2 2021 and a low of -$25.6 million during Q1 2022
  • Moreover, its 5-year median value for Cash from Operations was -$4.1 million (2023), whereas its average is $606473.7.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Cash from Operations crashed by 54516.65% in 2021 and then skyrocketed by 1001158.94% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Cash from Operations (Quarter) stood at -$19.1 million in 2021, then decreased by 14.79% to -$21.9 million in 2022, then soared by 71.52% to -$6.2 million in 2023, then skyrocketed by 332.42% to $14.5 million in 2024, then surged by 65.7% to $24.0 million in 2025.
  • Its Cash from Operations stands at $24.0 million for Q3 2025, versus $30.5 million for Q2 2025 and -$893000.0 for Q1 2025.